Stock EPRX EUPRAXIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Eupraxia Pharmaceuticals Inc.

Equities

EPRX

CA29842P1053

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 15:59:32 2024-05-16 EDT 		5-day change 1st Jan Change
3.96 CAD -1.00% Intraday chart for Eupraxia Pharmaceuticals Inc. 0.00% -26.26%
05-14 Eupraxia Pharmaceuticals Inc. Brief: Says To Present Initial Results from Ongoing Phase 1b Study of EP-104GI for Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024 MT
05-08 Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 34.89 78.81 146.5 142.5 - -
Enterprise Value (EV) 1 34.89 64.62 146.5 142.5 142.5 142.5
P/E ratio -1.32 x - - - - -
Yield - - - - - -
Capitalization / Revenue - - - - - 3.16 x
EV / Revenue - - - - - 3.16 x
EV / EBITDA - -3.42 x -5.29 x -4.75 x - -
EV / FCF - -4,129,724 x - - - -
FCF Yield - -0% - - - -
Price to Book - 5.48 x - 2.89 x 10.4 x 2.21 x
Nbr of stocks (in thousands) 14,243 21,593 27,282 35,623 - -
Reference price 2 2.450 3.650 5.370 4.000 4.000 4.000
Announcement Date 22-03-29 23-03-23 24-04-01 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - - 45.16
EBITDA 1 - - - -23.06 -27.69 -30 - -
EBIT 1 - - - -23.2 - -50.7 -57.62 -19.6
Operating Margin - - - - - - - -43.39%
Earnings before Tax (EBT) - - - - - - - -
Net income -7.176 -3.997 - - - - - -
Net margin - - - - - - - -
EPS -0.2900 -0.6500 -1.850 - - - - -
Free Cash Flow - - - -19.08 - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 21-02-10 21-03-30 22-03-29 23-03-23 24-04-01 - - -
1CAD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - -
EBIT 1 - - - - -8.802 -4.787 -7.649 -8.884 - -6.693 -11.63 -11.63 -18.28
Operating Margin - - - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - -
Net income - -3.691 - - - - - - - - - - -
Net margin - - - - - - - - - - - - -
EPS -0.2200 -0.2600 - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 22-03-29 22-05-05 22-08-12 22-11-07 23-03-23 23-05-11 23-08-11 23-11-14 24-04-01 24-05-08 - - -
1CAD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - 14.2 - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - -19.1 - - - -
ROE (net income / shareholders' equity) - - - -186% - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets - - - - - - - -
Book Value Per Share 1 - - - 0.6700 - 1.380 0.3800 1.810
Cash Flow per Share 1 - - - -0.9700 - 1.040 -1.000 1.440
Capex 2 - - - 0.31 - - - -
Capex / Sales - - - - - - - -
Announcement Date 21-02-10 21-03-30 22-03-29 23-03-23 24-04-01 - - -
1CAD2CAD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.96 CAD
Average target price
14.45 CAD
Spread / Average Target
+264.90%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EUPRAXIA PHARMACEUTICALS INC. Stock Eupraxia Pharmaceuticals Inc.
-26.26% 105M
MODERNA, INC. Stock Moderna, Inc.
+33.37% 49.46B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.55% 42.58B
LONZA GROUP AG Stock Lonza Group AG
+49.11% 42.49B
CELLTRION, INC. Stock Celltrion, Inc.
-4.22% 29.09B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.57% 26.61B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.00% 18.64B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+7.36% 13.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.30% 12.55B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+23.80% 12.1B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EPRX Stock
  4. Financials Eupraxia Pharmaceuticals Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW